Another GLP-1 receptor agonist semaglutide (Ozempic) is now on the PBS as a treatment option for patients with insufficiently controlled type 2 diabetes. The once-weekly glucose-lowering treatment is preferentially used as second and third line treatment in type 2 diabetes, particularly for patients at high risk of cardiovascular disease and in patients who are overweight ...
Type 2 diabetes
Semaglutide on the PBS for type 2 diabetes
By Mardi Chapman
1 Jul 2020